Syntax Bio is a synthetic biology company programming the next generation of cell therapy and organoid products. Its proprietary Cellgorithm platform uses a CRISPR-based system to program and accelerate stem cell differentiation, transforming how regenerative therapies are discovered and manufactured.

Syntax Bio's Cellgorithm technology overcomes the longstanding challenges in stem cell derived regenerative medicines by directly controlling and accelerating iPSC differentiation. By replacing slow, manual iPSC differentiation processes with a rapid, programmable approach that mimics human development, Syntax makes cell creation faster, more reliable, and scalable—unlocking new possibilities across cell therapy and gene therapy.